RET fusion-positive thyroid cancer
Roche withdraws Gavreto approval, citing study impracticality
SG Tylor
Roche’s cancer drug Gavreto was withdrawn for the treatment of advanced RET-mutant medullary thyroid cancer, following discussions with the FDA. ...
